EUVIMEDEUVIMED entdecken
VergleichsstudieEvaluationsstudieOpen Access · CC BY 4.0

Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL

Damiano Squitieri, Giulia Menchinelli, Carlotta Magrì, Tiziana D'Inzeo, Barbara Fiori, Margherita Cacaci, Maurizio Sanguinetti iD, Giulia De Angelis, Brunella Posteraro iD

Journal of Clinical Microbiology · 12.11.2025 · 63 (11)

DOI: 10.1128/jcm.01050-25 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 12.11.2025. Verfasst von Damiano Squitieri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Bacteremia, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Gram-Negative Bacteria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early antimicrobial susceptibility testing (AST) in Gram-negative (GN) bloodstream infections is critical to guide appropriate therapy. This study evaluated three rapid AST (RAST) systems—VITEK REVEAL, direct-from-blood-culture VITEK 2 (VITEK 2-RAST), and EUCAST disk diffusion (DD-RAST)—using 220 prospectively collected GN-positive blood cultures (GN-PBCs). A total of 18 GN species were tested, including Enterobacterales , Acinetobacter baumannii , and Pseudomonas aeruginosa , against 25 antibiotics, four of which were next-generation β-lactam/β-lactamase inhibitor (BL/BLI) antibiotics. Reference broth microdilution was used for comparison. The VITEK REVEAL assay showed 97.1% essential agreement (EA), −7.7 bias, and 98.3% categorical agreement (CA) across 3,603 organism/antibiotic combinations. The VITEK 2-RAST assay showed 96.2% EA, −10.4 bias, and 98.4% CA across 3,941 combinations. The DD-RAST assay showed 98.2% CA across 2,388 combinations. Among 164 GN-PBCs tested with all three assays, EA rates were 97.5% for VITEK REVEAL and 96.3% for VITEK 2-RAST, with bias values of −7.1 and −6.9, respectively. Across all three assays, the CA rate was ≥98.2%, and very major error (VME) rates were ≤1.8%. Mean time-to-result (TTR) was significantly shorter with VITEK REVEAL (6 h 32 min) compared to VITEK 2-RAST (13 h 51 min) and the fixed 8 h of DD-RAST. In resistant organisms, VITEK REVEAL produced significantly faster results than in susceptible or intermediate ones, including BL/BLI antibiotics. A. baumannii yielded the shortest TTR, with no observed VME. These results support the use of RAST directly on GN-PBCs, with VITEK REVEAL emerging as a particularly promising option for rapid and accurate testing. IMPORTANCE This study is the first to conduct a direct comparison of three rapid antimicrobial susceptibility testing (RAST) systems—VITEK REVEAL, VITEK 2-RAST, and DD-RAST—on a large, prospectively collected cohort of Gram-negative-positive blood cultures (GN-PBCs). The data offer valuable insights for laboratories evaluating RAST implementation, especially in EUCAST-based contexts. Among the systems tested, VITEK REVEAL stood out for its combination of rapid turnaround and high accuracy, including for antibiotic-resistant organisms and β-lactam/β-lactamase inhibitor (BL/BLI) antibiotics. These findings underscore the potential of RAST systems to deliver timely and reliable susceptibility results directly from GN-PBCs, thereby supporting more effective antimicrobial stewardship and clinical decision-making. However, the real-world impact will also depend on how well these systems integrate into routine workflows, as seamless implementation can directly affect time-to-result (TTR)—an essential element in optimizing the management of GN-bloodstream infection (BSI).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaGram-Negative Bacterial InfectionsAnti-Bacterial AgentsGram-Negative BacteriaHumansMicrobial Sensitivity TestsTime FactorsProspective StudiesBlood Culture

Stichwörter der Autor:innen

Gram-negative bacteriablood culturesminimum inhibitory concentrationrapid antimicrobial susceptibility testingtime to resultvolatile organic compounds

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Unità Operativa "Medicina di Precisione in Microbiologia Clinica", Direzione Scientifica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

ORCID-Profile: Maurizio Sanguinetti, Brunella Posteraro

Förderung

  • European Commission

Zitieren

APA

Squitieri, D., Menchinelli, G., Magrì, C., D'Inzeo, T., Fiori, B., Cacaci, M., Sanguinetti, M., De Angelis, G., & Posteraro, B. (2025). Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL. Journal of Clinical Microbiology, 63(11). https://doi.org/10.1128/jcm.01050-25

Vancouver

Squitieri D, Menchinelli G, Magrì C, D'Inzeo T, Fiori B, Cacaci M, et al. Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL. Journal of Clinical Microbiology. 2025;63(11). doi:10.1128/jcm.01050-25

BibTeX
@article{Squitieri2025,
  author = {Squitieri, Damiano and Menchinelli, Giulia and Magrì, Carlotta and D'Inzeo, Tiziana and Fiori, Barbara and Cacaci, Margherita and Sanguinetti, Maurizio and De Angelis, Giulia and Posteraro, Brunella},
  title = {Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  volume = {63},
  number = {11},
  doi = {10.1128/jcm.01050-25}
}
Kostenlos starten →